Next Article in Journal
Red Blood Cell-Derived Iron Alters Macrophage Function in COPD
Previous Article in Journal
A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma—Carcinoma Sequence
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 12
10.3390/biomedicines9121938
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

by
Mohd Imran
1,*,
Shah Alam Khan
2,
Mohammed Kanan Alshammari
3,
Meshal Ayedh Alreshidi
4,
Abeer Abdullah Alreshidi
4,
Rawan Sulaiman Alghonaim
5,
Fayez Aboud Alanazi
6,
Sultan Alshehri
7,
Mohammed M. Ghoneim
8 and
Faiyaz Shakeel
7,*
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia
2
College of Pharmacy, National University of Science and Technology, Muscat 130, Oman
3
Department of Pharmaceutical Care, Rafha Central Hospital, Rafha 91911, Saudi Arabia
4
Department of Pharmaceutical Care, King Khaled Hospital, Hail 81411, Saudi Arabia
5
Department of Supply, Qassim Armed Forces Hospital, Qassim 51922, Saudi Arabia
6
Department of Pharmaceutical Care, Al Yamamah Hospital, Riyadh 14814, Saudi Arabia
7
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
8
Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Biomedicines 2021, 9(12), 1938; https://doi.org/10.3390/biomedicines9121938
Submission received: 14 November 2021 / Revised: 9 December 2021 / Accepted: 14 December 2021 / Published: 17 December 2021
(This article belongs to the Section Drug Discovery and Development)
Browse Figures
Versions Notes

Abstract

The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival rate. Recent studies have indicated the involvement of epidermal growth factor receptor (EGFR) oncogene mutations like EGFR exon 20 insertions (EGFRex20ins) mutation among NSCLC patients. The response of patients of NSCLC with the EGFRex20ins mutation to the currently available EGFR inhibitor is negligible. Mobocertinib is the first oral treatment that has been approved by the USFDA, on 15 September 2021, to treat NSCLC with the EGFRex20ins mutation. This patent review discusses the inventions and patent literature of mobocertinib that will help the scientific community to develop additional and improved inventions related to mobocertinib. The structure of mobocertinib was first reported in 2015. Therefore, this article covered the patents/patent applications related to mobocertinib from 2015 to 25 October 2021. The patent search revealed 27 patents/patent applications related to compound, method of treatment, salt, polymorph, process, composition, and drug combinations of mobocertinib. The authors foresee an exciting prospect for developing a treatment for NSCLC with EGFRex20ins mutation, and other cancers employing a combination of mobocertinib with other approved anticancer agents. The inventions related to novel dosage forms, processes, and intermediates used in the synthesis of mobocertinib are also anticipated.
Keywords: mobocertinib; TAK-788; EGFR mutation; NSCLC; inventions; patent mobocertinib; TAK-788; EGFR mutation; NSCLC; inventions; patent

Share and Cite

MDPI and ACS Style

Imran, M.; Khan, S.A.; Alshammari, M.K.; Alreshidi, M.A.; Alreshidi, A.A.; Alghonaim, R.S.; Alanazi, F.A.; Alshehri, S.; Ghoneim, M.M.; Shakeel, F. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines 2021, 9, 1938. https://doi.org/10.3390/biomedicines9121938

AMA Style

Imran M, Khan SA, Alshammari MK, Alreshidi MA, Alreshidi AA, Alghonaim RS, Alanazi FA, Alshehri S, Ghoneim MM, Shakeel F. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines. 2021; 9(12):1938. https://doi.org/10.3390/biomedicines9121938

Chicago/Turabian Style

Imran, Mohd, Shah Alam Khan, Mohammed Kanan Alshammari, Meshal Ayedh Alreshidi, Abeer Abdullah Alreshidi, Rawan Sulaiman Alghonaim, Fayez Aboud Alanazi, Sultan Alshehri, Mohammed M. Ghoneim, and Faiyaz Shakeel. 2021. "Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions" Biomedicines 9, no. 12: 1938. https://doi.org/10.3390/biomedicines9121938

APA Style

Imran, M., Khan, S. A., Alshammari, M. K., Alreshidi, M. A., Alreshidi, A. A., Alghonaim, R. S., Alanazi, F. A., Alshehri, S., Ghoneim, M. M., & Shakeel, F. (2021). Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines, 9(12), 1938. https://doi.org/10.3390/biomedicines9121938

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop